ZURICH (Reuters) - Novartis said it resumed the production and delivery of radioligand therapy medicines after fixing the issues that had led to a temporary suspension of production last month.
ZURICH (Reuters) – Novartis said it resumed the production and delivery of radioligand therapy medicines after fixing the issues that had led to a temporary suspension of production last month.
“The company has remediated the issues that led to the temporary, voluntary suspension of production in May,” the Swiss drugmaker said in a statement, adding these issues did not affect patient safety.
(Reporting by Silke Koltrowitz; Editing by Paul Carrel)
Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products: